To NASDAQ OMX Copenhagen A/S
Announcement no. 12-13 / Copenhagen, April 12, 2013
Topotarget A/S’ Articles of Association following the capital increase of nom. DKK 22,500, the annual general meeting held on April 10, 2013, and warrants issue to employees, management, and the Board of Directors on April 11, 2013 are enclosed.
For further information, please contact:
Topotarget A/S
Anders Vadsholt, CEO: Direct: +45 39178345
About Topotarget
Topotarget (NASDAQ OMX: TOPO) is an international biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.
Topotarget Safe Harbor Statement
This announcement may contain forward-looking statements, including statements about Topotarget A/S’ expectations to the progression of Topotarget A/S’ clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.
